Compare McKesson Corporation (MCK) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Wells Fargo & Co — how do they compare? McKesson Corporation trades at $934.65 (market cap $108.46B), while Wells Fargo & Co trades at $82.21 (market cap $248.06B). The key difference: Wells Fargo & Co is far larger — about 2.3× McKesson Corporation's market cap, and Wells Fargo & Co pays the higher dividend (2.44%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Wells Fargo & Co for 87 Days on average.
| MCK | WFC | |
|---|---|---|
Market Cap | $108.46B | $248.06B |
Volume | 712,607 | 16,615,741 |
Sector | Health | Financials |
52-Week High | $995.69 | $96.40 |
52-Week Low | $725.17 | $73.42 |
Typical Hold Time | 74 Days | 87 Days |
Enterprise Value | $115.00B | $503.91B |
Dividend Yield | 0.4% | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.
The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.
Wells Fargo (WFC) trades at $80.26, down 1.53% today, with a bearish technical signal despite recent earnings beat in Q2 2026. The company shows strong fundamentals with a P/E of 11.92, net income margin of 25.97%, and a recent credit rating upgrade to 'A-' by S&P (Zacks Investment Research, 2026-10-01). Revenue growth is steady, reaching $83.70B in 2025, with a consensus price target of $99.13 suggesting upside potential.
The stock presents a value opportunity with attractive valuation metrics and improving profitability, but faces risks from volatile cash flows and regulatory changes in bank stress tests. Analyst sentiment is mixed with 46.66% buy ratings, while technical indicators signal near-term caution. Upside hinges on Q3 2026 earnings meeting expectations of $1.85 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
